about
Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimenMicelle-Based Adjuvants for Subunit Vaccine DeliveryMalaria endemicity and co-infection with tissue-dwelling parasites in Sub-Saharan Africa: a reviewA Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple FormulationsTLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN RoutesDevelopment of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical SynthesisObesity Outweighs Protection Conferred by Adjuvanted Influenza Vaccination.HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine developmentNovel Ricin Subunit Antigens With Enhanced Capacity to Elicit Toxin-Neutralizing Antibody Responses in Mice.A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant.Manipulation of EAT-2 expression promotes induction of multiple beneficial regulatory and effector functions of the human innate immune system as a novel immunomodulatory strategyAdjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.In Vivo Synthesis of Cyclic-di-GMP Using a Recombinant Adenovirus Preferentially Improves Adaptive Immune Responses against Extracellular Antigens.Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs.Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccinesLiposomes as vaccine delivery systems: a review of the recent advances.A comparative review of toll-like receptor 4 expression and functionality in different animal species.Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.Structure, size, and solubility of antigen arrays determines efficacy in experimental autoimmune encephalomyelitis.Adjuvants for vaccines to drugs of abuse and addiction.Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune PotentiatorsEnhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as AdjuvantSequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapyComparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future NeedsVaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondiiIgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens.Comparative Adjuvant Effects of Type II Heat-Labile Enterotoxins in Combination with Two Different Candidate Ricin Toxin Vaccine Antigens.Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "Meet the Experts" 2015 Workshop Summary.Role of G-CSF in monophosphoryl lipid A-mediated augmentation of neutrophil functions after burn injury.Influence of PapMV nanoparticles on the kinetics of the antibody response to flu vaccine.Human parainfluenza virus type 2 vector induces dendritic cell maturation without viral RNA replication/transcription.Targeting antigens to CD180 rapidly induces antigen-specific IgG, affinity maturation, and immunological memory.A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodiesAdjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.Comparative Transcriptome Profiles of Human Blood in Response to the Toll-like Receptor 4 Ligands Lipopolysaccharide and Monophosphoryl Lipid A.The immunobiology of toll-like receptor 4 agonists: from endotoxin tolerance to immunoadjuvants.Synthetic adjuvants for vaccine formulations: phytol derivatives.Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets.Skin-resident antigen-presenting cells: instruction manual for vaccine development.
P2860
Q21089693-B10610CB-4861-4301-8F47-9B9CB8425A85Q26783010-8466C8E6-87D4-407E-B26C-BC1B63792C2EQ26786020-4BC16CD5-960F-4F5D-A7ED-CF99A4A0CF57Q27321020-25E01B9B-539E-4BF1-AD10-0A83F2058242Q27322386-B14C956B-D304-4F45-A103-603AE075CDCDQ28829361-3C52E0E0-1940-4922-AA63-F7767B7DCA45Q30151873-D54B5508-8EB5-4255-ACD2-6ABE2238DE40Q30355260-C19532B3-E443-4AA3-92CB-9A6C2A694244Q30385759-C84E784A-EBA8-4D20-B064-1D2F4C8F6059Q30401247-326630E0-3022-4349-9F89-2A0F9302E447Q30423962-B7940F6A-7C39-4E5A-AC20-A1162D547CE5Q33749309-6B569206-14D6-46DB-A3BA-B407ECAE4C90Q33760871-DF7EAA75-3D5E-4CEB-BB78-2AB8A9115A4BQ33924419-AA862FEC-F18C-4298-9CCB-89BA4A0259DEQ33994987-15B58BF9-324A-47BC-ABAD-308CF9494829Q34057711-F6C32F5C-C15F-48C6-854E-B1C72D59CDB1Q34418761-F62B20E4-688D-4A65-986F-AF41932EC0CFQ34431296-A629A543-6A84-45D6-9E05-E0E923524548Q34600955-8A20F017-320F-428C-8CE7-F58D57025789Q35318199-EE914F04-6BCB-4119-9DBB-16C6450F0BC6Q35493923-AF710DDC-F757-4F9F-B48A-7220E3F33481Q35826747-149A3BF2-5E87-4DC0-A1A2-FDC29D7C7868Q36086281-9F79D8FC-4E55-43F6-A201-B7AFDC8AE69FQ36110892-3D015A09-CB9C-4EA0-BCAC-22E4FA4B9EB7Q36191001-52073244-BAB0-48DD-8A4D-A63B76676B94Q36240866-F6BB38A4-618A-40CE-8AAB-27A4BC64F857Q36294693-7B4A4A31-F1D6-4D1A-83FA-886E32A4C503Q36316776-F569A861-40F1-4F28-898A-4B8F9AAB7E43Q36601983-5EFC16A7-CC88-45D7-99E8-181E9A1B8990Q36676013-6865D608-2235-4B50-8E58-88F9902767DCQ36991329-B892EF0D-66AC-4C92-8C16-DB601C3BFAA1Q37035660-1C4D1884-4E6D-4440-A511-A5045AD3B118Q37194956-2127E492-8252-4D5A-B95B-6F26BCA56A67Q37264673-B12A5014-F094-48A3-92BB-D44D69590281Q37410524-EBF7E5D9-F6A5-4F2B-ABAD-2B478BDC6E0AQ37560510-C803CF27-6312-407A-88C6-509768F4899DQ37572673-0635D9CA-8A0A-4BC5-BC03-462C2DDB3BE3Q38072067-84E6191E-AC98-4502-A2FF-823A6367997FQ38096489-F329D895-FB5B-44F1-9CE3-98CFC913F52EQ38117141-51886E09-B300-4058-BBC9-CDCCB55842AA
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Adjuvants for human vaccines.
@en
type
label
Adjuvants for human vaccines.
@en
prefLabel
Adjuvants for human vaccines.
@en
P2093
P2860
P1476
Adjuvants for human vaccines.
@en
P2093
Carl R Alving
Kristina K Peachman
Mangala Rao
P2860
P304
P356
10.1016/J.COI.2012.03.008
P577
2012-04-19T00:00:00Z